Spero Therapeutics, Inc.
SPRO
$2.64
-$0.14-5.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.24% | -61.91% | -58.99% | -59.83% | -53.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.24% | -61.91% | -58.99% | -59.83% | -53.77% |
| Cost of Revenue | -94.22% | -47.42% | -12.22% | 20.98% | 41.16% |
| Gross Profit | 310.14% | -94.15% | -214.82% | -242.14% | -238.43% |
| SG&A Expenses | -10.66% | 3.69% | 5.79% | 1.89% | -7.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.49% | -20.38% | 7.52% | 40.14% | 56.46% |
| Operating Income | 109.88% | -3,984.60% | -370.16% | -370.26% | -370.59% |
| Income Before Tax | 112.88% | -1,306.26% | -367.30% | -368.31% | -369.90% |
| Income Tax Expenses | -- | 198.97% | -100.00% | -100.00% | -100.00% |
| Earnings from Continuing Operations | 112.50% | -1,347.82% | -407.08% | -398.09% | -400.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 112.50% | -1,347.82% | -407.08% | -398.09% | -400.65% |
| EBIT | 109.88% | -3,984.60% | -370.16% | -370.26% | -370.59% |
| EBITDA | 109.89% | -4,532.95% | -367.10% | -366.85% | -366.60% |
| EPS Basic | 111.90% | -1,076.54% | -390.60% | -390.00% | -397.61% |
| Normalized Basic EPS | 113.63% | -1,011.54% | -297.01% | -313.30% | -317.34% |
| EPS Diluted | 109.76% | -1,107.59% | -393.01% | -391.83% | -399.55% |
| Normalized Diluted EPS | 111.07% | -1,033.07% | -297.79% | -314.00% | -318.07% |
| Average Basic Shares Outstanding | 3.50% | 3.55% | 3.22% | 2.92% | 2.53% |
| Average Diluted Shares Outstanding | 5.05% | 3.50% | 3.17% | 2.87% | 2.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |